Background & methods	Concept model & data collection	Population characteristics, analytical validation	Reliability & validity	Longitudinal data	Conclusion	Acknowledgements & disclosure
	concection	👃 🐁 compliance 🔍				

Margaux Poleur¹, Barbara Willekens², Bertrand Degos³, Damien Ricard⁴, Vincent Van Pesch⁵, Oihana Piquet⁶, Alexis Tricot⁶, Laurie Médard¹, Hui Li⁶, Emilie Lommers⁷, Mona Michaud⁶, Anna-victoria De Keersmaecker², Irène Coman³, Paul Strijbos⁸, James Overell^{8,9}, Alexandra Goodyear¹⁰, Céline Cluzeau⁶, Damien Eggenspieler⁶, Laurent Servais¹¹

Affiliations: ¹University department of neurology, Citadelle Hospital of Liège; ²Department of Neurology, Antwerp University Hospital; ³Neurology Department, Avicenne Hospital, APHP, Hôpitaux Universitaires de Paris-Seine Saint Denis (HUPSSD); ⁴Service de Neurologie, Service de Santé des Armées, Hôpital d'Instruction des Armées de Percy; ⁵Cliniques Universitaires Saint-Luc, UCLouvain; ⁶SYSNAV; ⁷Department of neurology, Centre Hospitalier Universitaire de Liège; ⁸F. Hoffman-La Roche; ⁹Department of Clinical Neuroscience, School of Medicine, Dentistry and Nursing, University of Glasgow, UK; ¹⁰ Genentech, San Francisco, CA, USA; ¹¹MDUK Oxford Neuromuscular Centre, John Radcliffe Hospital.

Contact Information: Pr. Laurent SERVAIS laurent.servais@paediatrics.ox.ac.uk



Background & methods	Concept model & data collection	Population characteristics, analytical validation & compliance	Reliability & validity	Longitudinal data	Conclusion	Acknowledgements & disclosure
-------------------------	---------------------------------------	---	------------------------	----------------------	------------	----------------------------------

 Quantifying gait impairment, one of the main causes of disability in multiple sclerosis (MS), is an important step toward the quantification of disease progression

- The wearable Digital Health Technology (wDHT) is designed for patients' continuous assessment
- The 95th centile of stride velocity (SV95C) is the first digital clinical outcome measure qualified as a primary endpoint in Duchenne muscular dystrophy by the European Medicines Agency

Analytical validation & selection of candidate variables in **controlled environment**

 21 patients
 One visit: various gait exercices recorded with wDHT and a motion capture device

 \frown

I





ActiMS : one project, two study protocols

Validation of digital outcomes in **non-controlled environment**


• 78 patients


- 5 sites in Belgium and France
- Evaluation at baseline and at 1 year
- DHT worn for 3 months after the 1st visit and 1-3 months after the follow-up visit





		ground ethods Concept mod & data collection	characteristics, analytical validatio	n Reliability validity	&	Longitudinal data	Conclusion	Acknowledgements & disclosure		
			Controlled	Non-controlled	Z	Analytical validation	published on 21	patients:		
			environment	environment	0		0.07	-		
	ICS	Number of patients	21	78	AT	identified using the				
ш	ST	Age (years): median ± SD	39 ± 11.7	48.5 ± 11.7						
Z	R		[22-62]	[22-65]	∀					
	[range]		[22-02]			accurately detected				
SE	U U	Sex: female (%)	12 (54.5)	43 (55.1%)	۸L	by the wDHT	· · · · · · · · · · · · · · · · · · ·			
BA										
	A	EDSS: mean ± SD [range]	2.6 ± 1.3	3 ± 1.4	Ē	Centimetric precision ED55 ≤ 2 2 ≤ ED55	$2 \qquad 2 \le EDSS \le 3.5 \qquad EDSS \ge 4$			
	T25FW (seconds): mean ±		[1.5-5.5]	[0-5.5]		(median error on stride speed : 0.017 m/s)	' m/s)			
			5.3 ± 2.3	6.5 ± 6.7	AN4					
	SD [range]		[3.1-13.7]	[2.8-60.0]	$\overline{\triangleleft}$	 No significant imp 	act of the level o	of disability on the error		
			L J							
	L L	Number of patients	< 50 h of ≥ 50 h o	f ≥ 180 h of	99%	% and 94% of patients	at baseline and 1	1 year, respectively,		
		who recorded	data data	data		ve sufficient recorded				
<				uutu						
		Baseline, N (%)	1 (1%) 3 (4%)	74 (95%)	Not • 1	es: 4 patients withdrew				
	who recordedBaseline, N (%)1 year, N (%)		3 (6%) 7 (13%)	44 (81%)	 5 patients with no follow-up visit due to the departure of an investigator in one site 			ure of an investigator in		
	ר <u>ר</u>				-	patients are still collecting d	ata			





Background & methods	Concept model & data collection	Population characteristics, analytical validation & compliance	Reliability & validity	Longitudinal data	Conclusion	Acknowledgements & disclosure
-------------------------	---------------------------------------	---	------------------------	----------------------	------------	----------------------------------

- Wearable monitoring is feasible and patient burden is limited
- Selected wDHT is precise & accurate for stride detection & stride speed measurement in a heterogeneous ambulant population
- Digital outcomes derived from wDHT show internal and external consistency with gold standard measures of MS disability
- SV95C is sensitive to change over a 1-year period. Long-term data with shorter intervals between recording periods are currently being collected.

Background & methods	Concept model & data collection	Population characteristics, analytical validation & compliance	Reliability & validity	Longitudinal data	Conclusion	Acknowledgements & disclosure
		de compliance	<u> </u>			

Acknowledgements:

- We would like to thank all the patients, the investigators, study nurses, physiotherapists, and all the study teams.
- We would also like to express our gratitude to F. Hoffmann-La Roche for funding this study and for providing scientific expertise.

Disclosure:

Laurent Servais has given consultancy in the DMD field for Biogen, Novartis, Astellas, Evox, PTC, BioHaven, Zentech, MitoRX, Pfizer, Sarepta, Dyne, Santhera, Italfarmaco, Roche and SYSNAV.

He receives or received Personal Compensation for serving as scientific Advisory from Lupin, Fibrogen, Alltrana, Illumina and Roche.

He received Research Support from Roche, Novartis, Biogen, Zentech, BioHaven, PerkinHalmers, Scholar Rock.

He is PI for Sarepta, **Roche**, Italfarmaco, Wave Life Sciences.

